Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

pHH3 immunostaining improves interobserver agreement of mitotic index in thin melanomas.

Schimming TT, Grabellus F, Roner M, Pechlivanis S, Sucker A, Bielefeld N, Moll I, Schadendorf D, Hillen U.

Am J Dermatopathol. 2012 May;34(3):266-9. doi: 10.1097/DAD.0b013e31823135a3.

PMID:
22197861
2.

Useof anti-phosphohistone H3 immunohistochemistry to determine mitotic rate in thin melanoma.

Casper DJ, Ross KI, Messina JL, Sondak VK, Bodden CN, McCardle TW, Glass LF.

Am J Dermatopathol. 2010 Oct;32(7):650-4. doi: 10.1097/DAD.0b013e3181cf7cc1.

PMID:
20559123
3.

Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

J Invest Dermatol. 2012 Apr;132(4):1247-52. doi: 10.1038/jid.2011.464. Epub 2012 Feb 2.

4.

Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.

Fukushima S, Terasaki M, Sakata K, Miyagi N, Kato S, Sugita Y, Shigemori M.

Brain Tumor Pathol. 2009;26(2):51-7. doi: 10.1007/s10014-009-0249-9. Epub 2009 Oct 27.

PMID:
19856215
5.

Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.

Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z.

Am J Surg Pathol. 2015 Jan;39(1):13-24. doi: 10.1097/PAS.0000000000000341.

PMID:
25353284
6.

Immunohistochemical dual staining as an adjunct in assessment of mitotic activity in melanoma.

Ikenberg K, Pfaltz M, Rakozy C, Kempf W.

J Cutan Pathol. 2012 Mar;39(3):324-30. doi: 10.1111/j.1600-0560.2011.01858.x.

PMID:
22335591
7.

The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria.

Ribalta T, McCutcheon IE, Aldape KD, Bruner JM, Fuller GN.

Am J Surg Pathol. 2004 Nov;28(11):1532-6.

PMID:
15489659
8.

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma.

Ladstein RG, Bachmann IM, Straume O, Akslen LA.

BMC Cancer. 2010 Apr 14;10:140. doi: 10.1186/1471-2407-10-140.

9.

Immunohistochemical assessment of mitotic count in uveal melanoma.

Angi M, Damato B, Kalirai H, Dodson A, Taktak A, Coupland SE.

Acta Ophthalmol. 2011 Mar;89(2):e155-60. doi: 10.1111/j.1755-3768.2009.01769.x.

10.

Better see to better agree: phosphohistone H3 increases interobserver agreement in mitotic count for meningioma grading and imposes new specific thresholds.

Duregon E, Cassenti A, Pittaro A, Ventura L, Senetta R, Rudà R, Cassoni P.

Neuro Oncol. 2015 May;17(5):663-9. doi: 10.1093/neuonc/nov002. Epub 2015 Feb 1.

11.

Does mitosis-specific marker phosphohistone H3 help the grading of upper tract urothelial carcinomas in cell blocks?

Solomides CC, Birbe RC, Nicolaou N, Bagley D, Bibbo M.

Acta Cytol. 2012;56(3):285-8. doi: 10.1159/000337649. Epub 2012 Apr 26.

PMID:
22555531
12.

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.

Nielsen PS, Riber-Hansen R, Jensen TO, Schmidt H, Steiniche T.

Mod Pathol. 2013 Mar;26(3):404-13. doi: 10.1038/modpathol.2012.188. Epub 2012 Nov 23.

13.

Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.

Tetzlaff MT, Curry JL, Ivan D, Wang WL, Torres-Cabala CA, Bassett RL, Valencia KM, McLemore MS, Ross MI, Prieto VG.

Mod Pathol. 2013 Sep;26(9):1153-60. doi: 10.1038/modpathol.2013.59. Epub 2013 Apr 5.

14.

Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.

Kim YJ, Ketter R, Steudel WI, Feiden W.

Am J Clin Pathol. 2007 Jul;128(1):118-25.

PMID:
17580279
15.

Phosphohistone-H3 and Ki-67 immunostaining in cutaneous pilar leiomyoma and leiomyosarcoma (atypical intradermal smooth muscle neoplasm).

Idriss MH, Kazlouskaya V, Malhotra S, Andres C, Elston DM.

J Cutan Pathol. 2013 Jun;40(6):557-63. doi: 10.1111/cup.12127. Epub 2013 Apr 4.

PMID:
23550775
16.

Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors.

Uguen A, Conq G, Doucet L, Talagas M, Costa S, De Braekeleer M, Marcorelles P.

Virchows Arch. 2015 Jul;467(1):47-54. doi: 10.1007/s00428-015-1763-2. Epub 2015 Apr 1.

PMID:
25823616
17.

Analysis of tumor mitotic rate in thin metastatic melanomas compared with thin melanomas without metastasis using both the hematoxylin and eosin and anti-phosphohistone 3 IHC stain.

Thareja S, Zager JS, Sadhwani D, Thareja S, Chen R, Marzban S, Jukic DM, Glass LF, Messina J.

Am J Dermatopathol. 2014 Jan;36(1):64-7. doi: 10.1097/DAD.0b013e31829433b6.

PMID:
24451214
18.

Mitotic rate in melanoma: prognostic value of immunostaining and computer-assisted image analysis.

Hale CS, Qian M, Ma MW, Scanlon P, Berman RS, Shapiro RL, Pavlick AC, Shao Y, Polsky D, Osman I, Darvishian F.

Am J Surg Pathol. 2013 Jun;37(6):882-9. doi: 10.1097/PAS.0b013e31827e50fa.

19.

Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa.

Gunia S, Kakies C, Erbersdobler A, Koch S, May M.

J Clin Pathol. 2012 Aug;65(8):715-20. doi: 10.1136/jclinpath-2011-200532. Epub 2012 May 3.

PMID:
22554964
20.

Detection of mitotic figures in thin melanomas--immunohistochemistry does not replace the careful search for mitotic figures in hematoxylin-eosin stain.

Ottmann K, Tronnier M, Mitteldorf C.

J Am Acad Dermatol. 2015 Oct;73(4):637-44. doi: 10.1016/j.jaad.2015.07.007. Epub 2015 Aug 13.

PMID:
26278815

Supplemental Content

Support Center